Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSG | P08311 | 9/20 | 0.81 |
| ▸ | CMA1 | P23946 | 3/20 | 0.81 |
| ▸ | MASP2 | O00187 | 1/20 | 0.75 |
| ▸ | ACP3 | P15309 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | WNK1 | Q9H4A3 | 1/20 | 0.38 |
| ▸ | KLK7 | P49862 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30355342 | 0.90 | CTSG (1.00) | CTSGCMA1MASP2ACP3NPC1 | |
| SCHEMBL1260969 | 0.90 | CTSG (1.00) | CTSGCMA1MASP2ACP3NPC1 | |
| SCHEMBL30583367 | 0.90 | CTSG (1.00) | CTSGCMA1MASP2ACP3NPC1 | |
| SCHEMBL1614372 | 0.87 | CTSG (0.91) | CTSGCMA1MASP2ACP3NPC1 | |
| SCHEMBL1614715 | 0.86 | CTSG (0.89) | CTSGCMA1MASP2ACP3NPC1 | |
| SCHEMBL4456271 | 0.86 | CTSG (0.86) | CTSGCMA1MASP2ACP3MCHR1 | |
| SCHEMBL1613660 | 0.86 | CTSG (1.00) | CTSGCMA1MASP2ACP3NPC1 | |
| SCHEMBL31211813 | 0.86 | CTSG (1.00) | CTSGCMA1MASP2ACP3NPC1 | |
| SCHEMBL10146840 | 0.85 | CTSG (0.90) | CTSGCMA1MASP2ACP3NPC1 | |
| SCHEMBL4455609 | 0.85 | CTSG (0.90) | CTSGCMA1MASP2ACP3NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461195-B2 | Phosphonic acid compounds as inhibitors of serine proteases | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-06-11 | — | — | US | claimed |
| US-20110319363-A1 | NOVEL PHOSPHONIC ACID COMPOUNDS AS INHIBITORS OF SERINE PROTEASES | GRECO MICHAEL N (US) | 2011-12-29 | — | — | US | claimed |
| EP-1438316-B1 | PHOSPHONIC ACID COMPOUNDS AS INHIBITORS OF SERINE PROTEASES | ORTHO MCNEIL PHARM INC (US) | 2006-06-21 | — | — | EP | claimed |
| EP-1438316-A1 | PHOSPHONIC ACID COMPOUNDS AS INHIBITORS OF SERINE PROTEASES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2004-07-21 | — | — | EP | claimed |
| US-20040082544-A1 | Novel phosphonic acid compounds as inhibitors of serine proteases | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-04-29 | — | — | US | claimed |
| US-20030195172-A1 | Novel phosphonic acid compounds as inhibitors of serine proteases | GRECO MICHAEL N (US) | 2003-10-16 | — | — | US | claimed |
| WO-2003035654-A1 | PHOSPHONIC ACID COMPOUNDS AS INHIBITORS OF SERINE PROTEASES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2003-05-01 | — | — | WO | claimed |
| EP-1620446-B1 | PIPERAZINE CONTAINING PHOSPHONIC ACID COMPOUNDS AS INHIBITORS OF SERINE PROTEASES | ORTHO MCNEIL PHARMACEUTICAL CORP (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20090054319-A1 | Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders | MICROBIA, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2006102069-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION AND GASTROINTESTINAL DISORDERS | MICROBIA, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082544-A1 | Novel phosphonic acid compounds as inhibitors of serine proteases | HPN, PRSS1, SERPINB1 | CTSG 251/4885CMA1 137/4885MASP2 31/4885 |
| US-20030195172-A1 | Novel phosphonic acid compounds as inhibitors of serine proteases | HPN, PRSS1, SERPINB1 | CTSG 251/4885CMA1 137/4885MASP2 31/4885 |
| US-20110319363-A1 | NOVEL PHOSPHONIC ACID COMPOUNDS AS INHIBITORS OF SERINE PROTEASES | HPN, PRSS1, SERPINB1 | CTSG 251/4885CMA1 137/4885MASP2 31/4885 |
| US-20090054319-A1 | Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders | PTGIS, PTGIR, GRPR | CTSG 1249/4885CMA1 313/4885MASP2 3443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.